Previous Close | 8,582.00 |
Open | 8,650.00 |
Bid | 8,762.00 x 0 |
Ask | 8,766.00 x 0 |
Day's Range | 8,631.00 - 8,770.00 |
52 Week Range | 6,260.00 - 8,770.00 |
Volume | |
Avg. Volume | 1,511,888 |
Market Cap | 3.516T |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | 16.94 |
EPS (TTM) | 517.49 |
Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
Forward Dividend & Yield | 140.00 (1.63%) |
Ex-Dividend Date | Sep 28, 2023 |
1y Target Est | 9,007.10 |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Fujifilm Holdings Corp. (FUJIY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
FUJIFILM's (FUJIY) fourth-quarter performance benefits from solid momentum in Healthcare and Imaging Solutions business segments.
Is FUJIFILM (FUJIY) a great pick from the value investor's perspective right now? Read on to know more.
In this article, we will take a look at the 16 largest photography companies in the world. If you want to see more companies in this selection, go to the 5 Largest Photography Companies in the World. According to Zion Market Research, the size of the global digital photography market stood at $105.2 billion at […]
Fujifilm Holdings Corp. (FUJIY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FUJIFILM (FUJIY) and Utilization of Carbon Dioxide Institute form a partnership to develop mass production technology for alanine.
FUJIFILM (FUJIY) second-quarter performance gains from strong revenue growth in Medical Systems, Electronic Materials and Imaging business segment.
Fujifilm Holdings Corp (OTC: FUJIY) (OTC: FUJIF) has discontinued the development of its anti-influenza drug, Avigan (favipiravir), for use as a therapeutic drug against COVID-19. In 2021, Fujifilm Toyama Chemical began a phase 3 clinical trial in Japan with a target enrollment of 316 subjects to confirm Avigan's efficacy in preventing the progression to severe symptoms in COVID-19 patients who have not yet been vaccinated. However, enrollment was terminated at 84 subjects in March 2022 followin
FUJIFILM's (FUJIY) first-quarter (ended Jun 30, 2022) performance benefits from strength across all business segment.